PEMBROLIZUMAB AS SECOND-LINE THERAPY OF HEPATOCELLULAR CARCINOMA: A COST-EFFECTIVENESS ANALYSIS FROM THE UNITED KINGDOM HEALTHCARE PERSPECTIVE
Cheuk Yan Wong 1
Sik Kwan Chan 2
1 The University of Hong Kong, Pokfulam, Hong Kong, China (SAR)
2 The University of Hong Kong, Hong Kong, Hong Kong, China (SAR)
Session
Liver & biliary (Posters)
Conference
UEG Week Virtual 2020
Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]